Abstract
1 Various doses of verapamil, using the conventional and sustained release formulations, have been administered for the treatment of mild or moderate hypertension in different controlled studies for periods of 4-6 weeks, involving a total of 103 patients, and in one long-term trial for 1 year in 12 patients.
2 A double-blind comparison of verapamil and nifedipine showed that the two calcium antagonists had equal antihypertensive action. A significant blood pressure (BP) reduction was achieved with verapamil both at rest and during isometric exercise in the great majority of patients. No significant correlation was found between age and BP reduction, but pretreatment BP and pressure reduction correlated positively. Heart rate (HR) was moderately but significantly reduced by verapamil.
3 The established wide interindividual differences in verapamil pharmacokinetics were confirmed. There was no significant correlation between plasma drug concentrations and BP reduction, but the dosage regimens with the highest mean plasma drug concentrations were associated with the greatest mean reduction in BP. A moderate, but significant, prolongation of AV-conduction was demonstrated. QRS- and QT-intervals were unaffected.
4 Side-effects, with all formulations of verapamil, were generally mild and often transient. No significant haematological or metabolic effects were observed during long-term treatment.
5 It is concluded that the calcium antagonist verapamil is an effective and safe drug. It can be considered as an alternative drug in mild and moderate essential hypertension.
Keywords: calcium antagonists, verapamil, hypertension, metabolic effects, isometric work
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Dollery C. T. Does it matter how blood pressure is reduced? Clin Sci (Lond) 1981 Dec;61 (Suppl 7):413s–420s. doi: 10.1042/cs061413s. [DOI] [PubMed] [Google Scholar]
- Gould B. A., Mann S., Kieso H., Subramanian V. B., Raftery E. B. The role of a slow channel inhibitor, verapamil, in the management of hypertension. Acta Med Scand Suppl. 1984;681:117–123. doi: 10.1111/j.0954-6820.1984.tb08685.x. [DOI] [PubMed] [Google Scholar]
- Hulthén U. L., Bolli P., Bühler F. R. Calcium influx blockers in the treatment of essential hypertension. Acta Med Scand Suppl. 1984;681:101–108. doi: 10.1111/j.0954-6820.1984.tb08683.x. [DOI] [PubMed] [Google Scholar]
- Krikler D. Verapamil in cardiology. Eur J Cardiol. 1974 Aug;2(1):3–10. [PubMed] [Google Scholar]
- Lewis G. R., Morley K. D., Lewis B. M., Bones P. J. The treatment of hypertension with verapamil. N Z Med J. 1978 May 24;87(612):351–354. [PubMed] [Google Scholar]
- Lund-Johansen P. Haemodynamics in essential hypertension. Clin Sci (Lond) 1980 Dec;59 (Suppl 6):343s–354s. doi: 10.1042/cs059343s. [DOI] [PubMed] [Google Scholar]
- Lund-Johansen P. Hemodynamic effects of verapamil in essential hypertension at rest and during exercise. Acta Med Scand Suppl. 1984;681:109–115. doi: 10.1111/j.0954-6820.1984.tb08684.x. [DOI] [PubMed] [Google Scholar]
- Opie L. H. Drugs and the heart. III. Calcium antagonists. Lancet. 1980 Apr 12;1(8172):806–810. doi: 10.1016/s0140-6736(80)91303-3. [DOI] [PubMed] [Google Scholar]
- Pedersen O. L. Calcium blockade as a therapeutic principle in arterial hypertension. Clinical aspects and experimental studies on isolated vessels from spontaneously hypertensive rats and normotensive man. Acta Pharmacol Toxicol (Copenh) 1981;49 (Suppl 2):1–31. doi: 10.1111/j.1600-0773.1981.tb03365.x. [DOI] [PubMed] [Google Scholar]
- Stone P. H., Antman E. M., Muller J. E., Braunwald E. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Ann Intern Med. 1980 Dec;93(6):886–904. doi: 10.7326/0003-4819-93-6-886. [DOI] [PubMed] [Google Scholar]